BRPI0900798A8 - formulação contendo peptídeos associados a tumores que ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla), uso dos referidos peptídeos bem como kit compreendendo a referida formulação - Google Patents
formulação contendo peptídeos associados a tumores que ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla), uso dos referidos peptídeos bem como kit compreendendo a referida formulaçãoInfo
- Publication number
- BRPI0900798A8 BRPI0900798A8 BRPI0900798A BRPI0900798A BRPI0900798A8 BR PI0900798 A8 BRPI0900798 A8 BR PI0900798A8 BR PI0900798 A BRPI0900798 A BR PI0900798A BR PI0900798 A BRPI0900798 A BR PI0900798A BR PI0900798 A8 BRPI0900798 A8 BR PI0900798A8
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- formulation
- hla
- bind
- class
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- 238000009472 formulation Methods 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 210000000265 leukocyte Anatomy 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) uso dos referidos peptídeos bem kit compreendendo a referida formulação.. a presente invenção refere-se a formulações novas de peptideos associados a tumores que se ligam a moléculas da classe i ou ii do antígeno leucocitário humano (hla) como vacinas para serem utilizadas em métodos imunoterápicos. em particular, a presente invenção refere-se especificamente a formulações para a imunoterapia do câncer, em especial do câncer renal e câncer cerebral, em particular o glioma, especialmente o câncer tipo glioblastoma. além disso, a presente invenção refere-se a composições de vacinas para provocar respostas imunes antitumorais.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4766908P | 2008-04-24 | 2008-04-24 | |
| EP08008292A EP2113253B1 (en) | 2008-04-30 | 2008-04-30 | Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0900798A2 BRPI0900798A2 (pt) | 2010-01-19 |
| BRPI0900798A8 true BRPI0900798A8 (pt) | 2021-05-04 |
Family
ID=39643855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0900798A BRPI0900798A8 (pt) | 2008-04-24 | 2009-04-24 | formulação contendo peptídeos associados a tumores que ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla), uso dos referidos peptídeos bem como kit compreendendo a referida formulação |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9289478B2 (pt) |
| EP (2) | EP2113253B1 (pt) |
| JP (1) | JP5717268B2 (pt) |
| CN (1) | CN105749285A (pt) |
| AT (2) | ATE462442T1 (pt) |
| AU (1) | AU2009201589C1 (pt) |
| BR (1) | BRPI0900798A8 (pt) |
| CA (1) | CA2665510C (pt) |
| CY (1) | CY1110178T1 (pt) |
| DE (1) | DE602008000891D1 (pt) |
| DK (2) | DK2113253T3 (pt) |
| EA (1) | EA017492B1 (pt) |
| ES (2) | ES2342506T3 (pt) |
| HR (2) | HRP20100354T1 (pt) |
| MX (1) | MX2009004468A (pt) |
| NZ (1) | NZ576423A (pt) |
| PL (2) | PL2113253T3 (pt) |
| PT (2) | PT2113253E (pt) |
| RS (1) | RS52115B (pt) |
| SI (2) | SI2113253T1 (pt) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
| US8435507B2 (en) | 2004-08-19 | 2013-05-07 | University Of Maryland | Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer |
| BRPI0813621A2 (pt) | 2007-07-27 | 2017-05-09 | Immatics Biotechnologies Gmbh | imunoterapia contra tumores neuronais e cerebrais |
| HUE025636T2 (en) | 2007-07-27 | 2016-04-28 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
| CY1112212T1 (el) * | 2008-04-24 | 2015-12-09 | Immatics Biotechnologies Gmbh | Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια |
| DK2119726T5 (en) | 2008-05-14 | 2018-03-26 | Immatics Biotechnologies Gmbh | Novel and powerful MHC class II peptides derived from survivin and neurocan |
| EP2328919A2 (en) * | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| PL2350129T3 (pl) | 2008-08-25 | 2015-12-31 | Amplimmune Inc | Kompozycje antagonistów PD-1 i sposoby stosowania |
| AU2016204712B2 (en) * | 2008-10-01 | 2018-03-01 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
| AU2014271235B2 (en) * | 2008-10-01 | 2017-03-02 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including neuronal and brain tumors |
| EP2172211B1 (en) * | 2008-10-01 | 2014-12-03 | Immatics Biotechnologies GmbH | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| GB201019331D0 (en) | 2010-03-19 | 2010-12-29 | Immatics Biotechnologies Gmbh | Methods for the diagnosis and treatment of cancer based on AVL9 |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| AU2015200751B2 (en) * | 2010-03-19 | 2016-11-10 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| CA2821582A1 (en) * | 2010-12-14 | 2012-06-21 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| WO2013041542A1 (en) * | 2011-09-19 | 2013-03-28 | Alf Lamprecht | Pharmaceutical formulations comprising spherolyophilisates of biological molecules |
| JP6159996B2 (ja) * | 2012-03-09 | 2017-07-12 | 株式会社富士薬品 | ペプチドを含む医薬組成物 |
| CN110123763A (zh) | 2012-06-21 | 2019-08-16 | 法斯瑞斯公司 | 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法 |
| TWI819228B (zh) | 2013-08-05 | 2023-10-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八） |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| AU2016260540B2 (en) | 2015-05-13 | 2021-01-07 | Agenus Inc. | Vaccines for treatment and prevention of cancer |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| MX2017016213A (es) * | 2015-06-19 | 2018-03-07 | Immatics Biotechnologies Gmbh | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia y metodos para crear soportes para el uso contra el cancer de pancreas y otros tipos de cancer. |
| GB2544843B (en) * | 2015-07-14 | 2022-08-03 | Professional Compounding Centers Of America Pcca | Poloxamer-based intralesional injections for the delivery of chemotherapeutic agents |
| BR112018012374A2 (pt) | 2015-12-16 | 2018-12-04 | Gritstone Oncology, Inc. | identificação, fabricação e uso de neoantígeno |
| GB201604490D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides combination of peptides for use in immunotherapy against cancers |
| CR20190388A (es) * | 2017-01-27 | 2019-10-16 | Immatics Biotechnologies Gmbh | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer |
| US10738100B2 (en) | 2017-01-27 | 2020-08-11 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| WO2018138257A1 (en) * | 2017-01-27 | 2018-08-02 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| JP7227237B2 (ja) | 2017-10-10 | 2023-02-21 | グリットストーン バイオ インコーポレイテッド | ホットスポットを利用した新生抗原の特定 |
| KR102905054B1 (ko) | 2017-11-22 | 2025-12-29 | 시애틀 프로젝트 코포레이션 | 신생항원에 대한 접합 에피토프 제시 감소 |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| KR20210005646A (ko) | 2018-04-26 | 2021-01-14 | 아게누스 인코포레이티드 | 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법 |
| FR3087448B1 (fr) | 2018-10-23 | 2023-10-13 | Pdc Line Pharma | Lignee pdc modifiee pour secreter une cytokine |
| WO2021231405A1 (en) * | 2020-05-12 | 2021-11-18 | Board Of Regents, The University Of Texas System | Methods for treating glioblastoma |
| DE102020125465A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| CN118647394A (zh) | 2022-02-03 | 2024-09-13 | 赛科维有限两合公司 | 使用cd4和cd8抗原的共疫苗接种 |
| EP4410767B1 (de) | 2023-02-03 | 2025-10-01 | Röhm GmbH | Nachhaltiges c3 verfahren mit integrierter erzeugung von rohstoffen |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6045796A (en) * | 1992-12-17 | 2000-04-04 | Anergen, Inc. | Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| CA2226575C (en) * | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US5861483A (en) * | 1996-04-03 | 1999-01-19 | Pro-Neuron, Inc. | Inhibitor of stem cell proliferation and uses thereof |
| US20030162711A1 (en) * | 1996-04-24 | 2003-08-28 | Soren Bjorn | Pharmaceutical formulation |
| US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| DE19917195B4 (de) | 1999-04-16 | 2006-09-28 | Immatics Biotechnologies Gmbh | Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor |
| US6897288B1 (en) * | 1999-10-19 | 2005-05-24 | Ludwig Institute For Cancer Research | Mage-A12 antigenic peptides and uses thereof |
| CN1402782A (zh) * | 1999-10-19 | 2003-03-12 | 路德维哥癌症研究院 | Mage－a12抗原肽及其应用 |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| DK2283856T3 (da) * | 2002-06-21 | 2017-11-20 | Novo Nordisk Healthcare Ag | Stabiliserede, faste sammensætninger af Faktor VIIa-polypeptider |
| AU2003256912A1 (en) * | 2002-08-16 | 2004-03-03 | Yeda Research And Development Co. Ltd. | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines |
| CA2521809A1 (en) * | 2003-04-11 | 2004-10-28 | Antigenics Inc. | Improved heat shock protein-based vaccines and immunotherapies |
| AR048098A1 (es) * | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| DE102004026135A1 (de) * | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| US20080125361A1 (en) * | 2004-11-12 | 2008-05-29 | Novo Nordisk A/S | Stable Formulations Of Peptides |
| EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| EP1717245B1 (en) * | 2005-04-26 | 2011-06-08 | Immatics Biotechnologies GmbH | T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof |
| ATE461214T1 (de) | 2005-09-05 | 2010-04-15 | Immatics Biotechnologies Gmbh | Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden |
| PT1760089E (pt) | 2005-09-05 | 2009-10-19 | Immatics Biotechnologies Gmbh | Peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antigénio leucocitário humano (hla) e correspondente vacina anti-cancerígena |
| WO2007028753A2 (de) | 2005-09-09 | 2007-03-15 | Basf Aktiengesellschaft | Fungizide mischungen auf der basis von triazolen |
| US20080242606A1 (en) * | 2006-06-06 | 2008-10-02 | Zhong Jiang | Use of IMP3 as a Prognostic Marker for Cancer |
| DK2119726T5 (en) * | 2008-05-14 | 2018-03-26 | Immatics Biotechnologies Gmbh | Novel and powerful MHC class II peptides derived from survivin and neurocan |
| EP2172211B1 (en) * | 2008-10-01 | 2014-12-03 | Immatics Biotechnologies GmbH | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
-
2008
- 2008-04-30 AT AT08008292T patent/ATE462442T1/de active
- 2008-04-30 SI SI200830038T patent/SI2113253T1/sl unknown
- 2008-04-30 EP EP08008292A patent/EP2113253B1/en active Active
- 2008-04-30 DK DK08008292.8T patent/DK2113253T3/da active
- 2008-04-30 ES ES08008292T patent/ES2342506T3/es active Active
- 2008-04-30 PT PT08008292T patent/PT2113253E/pt unknown
- 2008-04-30 DE DE602008000891T patent/DE602008000891D1/de active Active
- 2008-04-30 PL PL08008292T patent/PL2113253T3/pl unknown
-
2009
- 2009-04-23 CN CN201610085112.0A patent/CN105749285A/zh active Pending
- 2009-04-23 AU AU2009201589A patent/AU2009201589C1/en not_active Ceased
- 2009-04-23 PT PT09005725T patent/PT2111867E/pt unknown
- 2009-04-23 EP EP09005725A patent/EP2111867B1/en active Active
- 2009-04-23 NZ NZ576423A patent/NZ576423A/en not_active IP Right Cessation
- 2009-04-23 US US12/428,893 patent/US9289478B2/en active Active
- 2009-04-23 RS RS20110588A patent/RS52115B/sr unknown
- 2009-04-23 AT AT09005725T patent/ATE526979T1/de active
- 2009-04-23 JP JP2009104886A patent/JP5717268B2/ja active Active
- 2009-04-23 SI SI200930119T patent/SI2111867T1/sl unknown
- 2009-04-23 PL PL09005725T patent/PL2111867T3/pl unknown
- 2009-04-23 ES ES09005725T patent/ES2374138T3/es active Active
- 2009-04-23 DK DK09005725.8T patent/DK2111867T3/da active
- 2009-04-23 EA EA200900487A patent/EA017492B1/ru not_active IP Right Cessation
- 2009-04-24 CA CA2665510A patent/CA2665510C/en not_active Expired - Fee Related
- 2009-04-24 MX MX2009004468A patent/MX2009004468A/es active IP Right Grant
- 2009-04-24 BR BRPI0900798A patent/BRPI0900798A8/pt not_active Application Discontinuation
-
2010
- 2010-06-09 CY CY20101100508T patent/CY1110178T1/el unknown
- 2010-06-28 HR HR20100354T patent/HRP20100354T1/hr unknown
-
2011
- 2011-12-21 HR HR20110965T patent/HRP20110965T1/hr unknown
-
2012
- 2012-01-09 US US13/346,197 patent/US9283267B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0900798A8 (pt) | formulação contendo peptídeos associados a tumores que ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla), uso dos referidos peptídeos bem como kit compreendendo a referida formulação | |
| DK1922334T3 (da) | Tumorassocierede peptider, der binder til humant leukocyt antigen (HLA) klasse I eller II molekyler og dertil hørende anti-cancervaccine | |
| ATE451388T1 (de) | Tumorassoziierte peptide, die promiskuitiv an humane leukozytenantigen- (hla-) moleküle der klasse ii binden | |
| EA202190587A2 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
| IN2014CN03936A (pt) | ||
| NZ714163A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| UA104572C2 (ru) | Новые композиции опухолеассоциированных пептидов, которые связываются с молекулами i или ii класса лейкоцитарного антигена человека (hla) для разработки вакцин | |
| MD3236985T2 (ro) | Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva carcinomului hepatocelular (HCC) și altor cancere | |
| CY1112212T1 (el) | Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B03H | Publication of an application: rectification [chapter 3.8 patent gazette] |
Free format text: REFERENTE A RPI 2037 DE 19/01/2010, QUANTO AO ITEM (54) |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |